Search Results

Your search for Jack Cuzick, PhD, FMedSci matches 2 pages

Showing 1 - 2

By Jack Cuzick, PhD, FMedSci / 2015 San Antonio Breast Cancer Symposium

Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen

Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)

breast cancer

issues in oncology

By The ASCO Post Staff / Thursday, March 20, 2014 3:03 PM

Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy

Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...

Jan

Today In Oncology

Search Results

Your search for Jack Cuzick, PhD, FMedSci matches 2 pages

Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen

Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy

Nuclear Speckle Signatures in Clear Cell RCC

Maintenance Therapy After Induction With RVd With or Without Isatuximab in Transplant-Eligible Newly Diagnosed Multiple Myeloma

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

NPM1 Genotypes and Outcomes in AML

Studies Point to the Role of Diet in Hematologic Malignancies